Karen has over 26 years of experience in the biopharma industry, in a variety of commercial and strategic consulting roles. She started her career as a pharmaceutical sales representative and was promoted into increasing levels of responsibility eventually having managerial oversight for primary care and specialty sales teams across the US for Pfizer and AstraZeneca.
Karen moved into the global early access area in 2010 first with Clinigen Group, then Caligor Coghlan Pharma Services. During this time, she was responsible for helping biotech and pharma companies establish strategies and implementation of early access programs for their innovative medicines, with a special focus on orphan drugs and oncology. In 2019, she joined Alnylam Pharmaceuticals to lead the strategy and operational execution of early access programs and compassionate use across their pipeline.
Karen graduated with honors and holds a BS in Biology from the University of Akron. She has been a contributor to several patient facing publications which center around obtaining early access to medicines as well as a frequent presenter at rare disease industry conferences over the past 9 years.
· Outline your philosophy and access principles as the basis for formulating your patient access strategy
· Consider your market selection and individual market requirements while selecting access approach and strategy
· Begin with the end in mind – look at your late stage access requirements and plans for commercialisation as you map your strategy to avoid the need for back peddling